Open Monoclonal Technology (OMT) Announces Alliance with BCRT

Palo Alto, California, October 30, 2015
Open Monoclonal Technology, Inc. (OMT) today announced an alliance that provides the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) with access to OMT's OmniRat®, OmniMouse® and OmniFlic™ human antibody generation platforms.

BCRT is supported by Charité-Universitätsmedizin Berlin, Helmholtz-Zentrum Geesthacht, the German Federal Ministry of Education and Research, and the States of Berlin and Brandenburg. The mission of the BCRT is to translate new diagnostic and therapeutic approaches from bench-to-bedside.

The institution will be OMT's 2nd academic partner with such unlimited OmniAb™ access. Professor, Hans-Dieter Volk, MD, said "Human monoclonal antibodies enable completely new options for targeted therapy. The BCRT at the Charité will implement a core unit to generate antibodies against novel targets by using OMT's innovative technology platforms particularly for therapies in immunological diseases, regenerative medicine and oncology."

Dr. Roland Buelow, OMT founder and CEO, continued "The BCRT becomes OMT's second academic and 18th global partner with unlimited platform access. OMT looks forward to combining the world-class biological-clinical research of the BCRT with OMT's industry-leading transgenic animal platforms to make further strides in treating challenging human diseases."

Press release by OMT:

<- Back to: News & Events